Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

Citations Database Search Results

Download these results to MS Excel

335 records found for:
Title = Schizophrenia
Year =

  1. Luther L, Fischer MW, Johnson-Kwochka AV, Minor KS, Holden R, Lapish CL, McCormick B, Salyers MP. Mobile enhancement of motivation in schizophrenia: A pilot randomized controlled trial of a personalized text message intervention for motivation deficits. Journal of consulting and clinical psychology. 2020 Aug 13.
  2. Davis BJ, Lysaker PH, Salyers MP, Minor KS. The insight paradox in schizophrenia: A meta-analysis of the relationship between clinical insight and quality of life. Schizophrenia Research. 2020 Aug 3.
  3. Medenblik AM, Mann AM, Beaver TA, Dedert EA, Wilson SM, Calhoun PS, Beckham JC. Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia. Journal of Dual Diagnosis. 2020 Jul 31; 1-9.
  4. Kern RS, Reddy LF, Cohen AN, Young AS, Green MF. Effects of aerobic exercise on cardiorespiratory fitness and social functioning in veterans 40 to 65 years old with schizophrenia. Psychiatry Research. 2020 Sep 1; 291:113258.
  5. Ahearn EP, Szymanski BR, Chen P, Sajatovic M, Katz IR, McCarthy JF. Increased Risk of Dementia Among Veterans With Bipolar Disorder or Schizophrenia Receiving Care in the VA Health System. Psychiatric services (Washington, D.C.). 2020 Jun 10; appips201900325.
  6. Marggraf MP, Lysaker PH, Salyers MP, Minor KS. The link between formal thought disorder and social functioning in schizophrenia: A meta-analysis. European psychiatry : the journal of the Association of European Psychiatrists. 2020 Mar 23; 1-43.
  7. Appaji A, Nagendra B, Chako DM, Padmanabha A, Hiremath CV, Jacob A, Varambally S, Kesavan M, Venkatasubramanian G, Rao SV, Webers CAB, Berendschot TTJM, Rao NP. Retinal vascular fractal dimension in bipolar disorder and schizophrenia. Journal of affective disorders. 2019 Dec 1; 259:98-103.
  8. de Zwarte SMC, Brouwer RM, Agartz I, Alda M, Aleman A, Alpert KI, Bearden CE, Bertolino A, Bois C, Bonvino A, Bramon E, Buimer EEL, Cahn W, Cannon DM, Cannon TD, Caseras X, Castro-Fornieles J, Chen Q, Chung Y, De la Serna E, Di Giorgio A, Doucet GE, Eker MC, Erk S, Fears SC, Foley SF, Frangou S, Frankland A, Fullerton JM, Glahn DC, Goghari VM, Goldman AL, Gonul AS, Gruber O, de Haan L, Hajek T, Hawkins EL, Heinz A, Hillegers MHJ, Hulshoff Pol HE, Hultman CM, Ingvar M, Johansson V, Jönsson EG, Kane F, Kempton MJ, Koenis MMG, Kopecek M, Krabbendam L, Krämer B, Lawrie SM, Lenroot RK, Marcelis M, Marsman JC, Mattay VS, McDonald C, Meyer-Lindenberg A, Michielse S, Mitchell PB, Moreno D, Murray RM, Mwangi B, Najt P, Neilson E, Newport J, van Os J, Overs B, Ozerdem A, Picchioni MM, Richter A, Roberts G, Aydogan AS, Schofield PR, Simsek F, Soares JC, Sugranyes G, Toulopoulou T, Tronchin G, Walter H, Wang L, Weinberger DR, Whalley HC, Yalin N, Andreassen OA, Ching CRK, van Erp TGM, Turner JA, Jahanshad N, Thompson PM, Kahn RS, van Haren NEM. The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. Biological psychiatry. 2019 Oct 1; 86(7):545-556.
  9. Bonfils KA, Haas GL, Salyers MP. Emotion-specific performance across empathy tasks in schizophrenia: Influence of metacognitive capacity. Schizophrenia research. Cognition. 2020 Mar 1; 19:100139.
  10. Luther L, Bonfils KA, Fischer MW, Johnson-Kwochka AV, Salyers MP. Metacognition moderates the relationship between self-reported and clinician-rated motivation in schizophrenia. Schizophrenia research. Cognition. 2020 Mar 1; 19:100140.
  11. Nuttall AK, Thakkar KN, Luo X, Mueser KT, Glynn SM, Achtyes ED, Kane JM. Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study. Psychiatry Research. 2019 Jun 1; 276:60-68.
  12. Cohen AN, Pedersen ER, Glynn SM, Hamilton AB, McNagny KP, Reist C, Chemerinski E, Young AS. Preferences for family involvement among veterans in treatment for schizophrenia. Psychiatric Rehabilitation Journal. 2019 Sep 1; 42(3):210-219.
  13. Lysaker P, Kukla ME, Vohs JL, Schnakenberg Martin AM, Buck KD, Hasson Ohayon I. Metacognition and recovery in schizophrenia: From research to the development of Metacognitive Reflection and Insight Therapy. Journal of Experimental Psychopathology. 2019 Feb 27; 10(1):https://doi.org/10.1177/2043808718814992.
  14. Cohen AN, Rocchio R. Developing and Initial Testing of a Mobile App Delivering an Evidence-based Weight Management Program to Veterans with Schizophrenia: CoachToFit. Spotlight on Mental Health Centers of Excellence [Cyberseminar]. VA HSR&D. 2019 Feb 11.
  15. Cohen AN. Addressing Obesity in the Population with Schizophrenia. American Psychiatric Association; 2019 Jan 31. Available from: https://education.smiadviser.org/Users/ProductDetails.aspx?ActivityID=6451.
  16. Treichler EBH, Thomas ML, Bismark AW, Hochberger WC, Tarasenko M, Nungaray J, Cardoso L, Joshi YB, Zhang W, Sprock J, Swerdlow N, Cohen AN, Light GA. Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia. Schizophrenia Research. 2019 Aug 1; 210:215-220.
  17. Bonfils KA, Lysaker PH, Minor KS, Salyers MP. Metacognition, Personal Distress, and Performance-Based Empathy in Schizophrenia. Schizophrenia Bulletin. 2019 Jan 1; 45(1):19-26.
  18. Lysaker PH, Gagen E, Wright A, Vohs JL, Kukla M, Yanos PT, Hasson-Ohayon I. Metacognitive Deficits Predict Impaired Insight in Schizophrenia Across Symptom Profiles: A Latent Class Analysis. Schizophrenia Bulletin. 2019 Jan 1; 45(1):48-56.
  19. Young AS, Cohen AN, Hamilton AB, Hellemann G, Reist C, Whelan F. Implementing Patient-Reported Outcomes to Improve the Quality of Care for Weight of Patients with Schizophrenia. The journal of behavioral health services & research. 2019 Jan 1; 46(1):129-139.
  20. Luther L, Fischer MW, Firmin RL, Salyers MP. Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis. Schizophrenia Research. 2019 Apr 1; 206:27-36.
  21. Achtyes ED, Ben-Zeev D, Luo Z, Mayle H, Burke B, Rotondi AJ, Gottlieb JD, Brunette MF, Mueser KT, Gingerich S, Meyer-Kalos PS, Marcy P, Schooler NR, Robinson DG, Kane JM. Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. Schizophrenia Research. 2019 Apr 1; 206:200-208.
  22. Lysaker P, Hamm JA, Vohs J, Kukla ME, Pattison ML, Leonhardt BL, Lysaker JT. Understanding the course of self-disorders and alterations in self-experience in schizophrenia: Implications from research on metacognition. Current psychiatry reviews. 2018 Dec 1; 14(3):DOI : 10.2174/1573400514666180816113159.
  23. Wilson SM, Thompson AC, Currence ED, Thomas SP, Dedert EA, Kirby AC, Elbogen EB, Moore SD, Calhoun PS, Beckham JC. Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. Behavior Therapy. 2019 Mar 1; 50(2):395-409.
  24. Kukla M, Bell MD, Lysaker PH. A randomized controlled trial examining a cognitive behavioral therapy intervention enhanced with cognitive remediation to improve work and neurocognition outcomes among persons with schizophrenia spectrum disorders. Schizophrenia Research. 2018 Jul 1; 197:400-406.
  25. Hansen RA, Hohmann N, Maciejewski ML, Domino ME, Ray N, Mahendraratnam N, Farley JF. Continuity of Medication Management among Adults with Schizophrenia and Comorbid Cardiometabolic Conditions. Journal of pharmaceutical health services research: an official journal of the Royal Pharmaceutical Society of Great Britain. 2018 Mar 1; 9(1):13-20.
  26. Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-Koch AE, Baker DG, Beckham JC, Bierut LJ, Bisson J, Bradley B, Chen CY, Dalvie S, Farrer LA, Galea S, Garrett ME, Gelernter JE, Guffanti G, Hauser MA, Johnson EO, Kessler RC, Kimbrel NA, King A, Koen N, Kranzler HR, Logue MW, Maihofer AX, Martin AR, Miller MW, Morey RA, Nugent NR, Rice JP, Ripke S, Roberts AL, Saccone NL, Smoller JW, Stein DJ, Stein MB, Sumner JA, Uddin M, Ursano RJ, Wildman DE, Yehuda R, Zhao H, Daly MJ, Liberzon I, Ressler KJ, Nievergelt CM, Koenen KC. Largest GWAS of PTSD (N=20?070) yields genetic overlap with schizophrenia and sex differences in heritability. Molecular Psychiatry. 2018 Mar 1; 23(3):666-673.
  27. Humphreys K. A Review of the Impact of Exclusion Criteria on the Generalizability of Schizophrenia Treatment Research. Clinical schizophrenia & related psychoses. 2017 Apr 1; 11(1):49-57.
  28. Pedersen ER, Huang W, Cohen AN, Young AS. Alcohol use and service utilization among veterans in treatment for schizophrenia. Psychological Services. 2018 Feb 1; 15(1):21-30.
  29. Tang Y, Horvitz-Lennon M, Gellad WF, Lave JR, Chang CH, Normand SL, Donohue JM. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. Psychiatric services (Washington, D.C.). 2017 Jun 1; 68(6):579-586.
  30. Bradford DW, Goulet J, Hunt M, Cunningham NC, Hoff R. A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer. The Journal of clinical psychiatry. 2016 Dec 1; 77(12):e1626-e1630.
  31. Cohen AN, Hamilton AB, Saks ER, Glover DL, Glynn SM, Brekke JS, Marder SR. How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. Psychiatric services (Washington, D.C.). 2017 Apr 1; 68(4):324-329.
  32. Baumel A, Correll CU, Hauser M, Brunette M, Rotondi A, Ben-Zeev D, Gottlieb JD, Mueser KT, Achtyes ED, Schooler NR, Robinson DG, Gingerich S, Marcy P, Meyer-Kalos P, Kane JM. Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. Psychiatric services (Washington, D.C.). 2016 Sep 1; 67(9):1035-8.
  33. Ben-Zeev D, Scherer EA, Gottlieb JD, Rotondi AJ, Brunette MF, Achtyes ED, Mueser KT, Gingerich S, Brenner CJ, Begale M, Mohr DC, Schooler N, Marcy P, Robinson DG, Kane JM. mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. JMIR mental health. 2016 Jul 27; 3(3):e34.
  34. Kasckow J, Zickmund S, Gurklis J, Luther J, Fox L, Taylor M, Richmond I, Haas GL. Using telehealth to augment an intensive case monitoring program in veterans with schizophrenia and suicidal ideation: A pilot trial. Psychiatry Research. 2016 May 30; 239:111-6.
  35. Rotondi AJ. Development and Usability Testing of a Web-Based Smoking Cessation Treatment for Smokers with Schizophrenia. Internet interventions. 2016 May 21; 444-447.
  36. Brunette MF, Rotondi AJ, Ben-Zeev D, Gottlieb JD, Mueser KT, Robinson DG, Achtyes ED, Gingerich S, Marcy P, Schooler NR, Meyer-Kalos P, Kane JM. Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. Psychiatric services (Washington, D.C.). 2016 Apr 1; 67(4):444-7.
  37. Kasckow JW, Chen C, Rajj TK, Fraser C. Late Life Schizophrenia: Advances in Research. Presented at: American Association for Geriatric Psychiatry Annual Meeting; 2016 Mar 17; Washington, DC.
  38. Radhakrishnan R, Kiluk BD, Tsai J. A Meta-analytic Review of Non-specific Effects in Randomized Controlled Trials of Cognitive Remediation for Schizophrenia. The Psychiatric quarterly. 2016 Mar 1; 87(1):57-62.
  39. Yao JK, Dougherty GG, Gautier CH, Haas GL, Condray R, Kasckow JW, Kisslinger BL, Gurklis JA, Messamore E. Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia. Schizophrenia Bulletin. 2016 Mar 1; 42(2):369-76.
  40. Daniels KS, Kasckow JW. Reduction of Medical Hospitalizations in Veterans With Schizophrenia Using Home Telehealth. Presented at: American Psychiatric Association Institute on Psychiatric Services Annual Conference; 2015 Oct 10; New York, NY.
  41. Janney CA, Ganguli R, Tang G, Cauley JA, Holleman RG, Richardson CR, Kriska AM. Physical activity and sedentary behavior measured objectively and subjectively in overweight and obese adults with schizophrenia or schizoaffective disorders. The Journal of clinical psychiatry. 2015 Oct 1; 76(10):e1277-84.
  42. Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Journal of managed care & specialty pharmacy. 2015 Sep 1; 21(9):754-68.
  43. Daniels KS, Loganathan M, Wilson R, Kasckow JW. Appointment attendance in patients with schizophrenia. Therapy. 2015 Aug 1; 11(4):467-482.
  44. Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. Journal of Clinical Psychopharmacology. 2015 Aug 1; 35(4):442-6.
  45. Sullivan G, Mittal D, Reaves CM, Haynes TF, Han X, Mukherjee S, Morris S, Marsh L, Corrigan PW. Influence of schizophrenia diagnosis on providers' practice decisions. The Journal of clinical psychiatry. 2015 Aug 1; 76(8):1068-74; quiz 1074.
  46. Cohen AN, Chinman MJ, Hamilton AB, Whelan F, Young AS. Patient-facing kiosks for Veterans with schizophrenia: reducing risk by dynamically identifying service needs. Paper presented at: VA HSR&D / QUERI National Meeting; 2015 Jul 9; Philadelphia, PA.
  47. Grubaugh AL, Knapp RG, Ellis C, Veronee K. Reactions to Exposure Therapy for PTSD Among Patients with Schizophrenia. Poster session presented at: VA HSR&D / QUERI National Meeting; 2015 Jul 8; Philadelphia, PA.
  48. Lysaker PH, Vohs J, Minor KS, Irarrázaval L, Leonhardt B, Hamm JA, Kukla M, Popolo R, Luther L, Buck KD, Wasmuth S, Dimaggio G. Metacognitive Deficits in Schizophrenia: Presence and Associations With Psychosocial Outcomes. The Journal of nervous and mental disease. 2015 Jul 1; 203(7):530-6.
  49. Tan Y, Horvitz-Lennon M, Gellad WF, Normand SL, Donohue JM. Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program. Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2015 May 19; Philadelphia, PA.
  50. Minor KS, Bonfils KA, Luther L, Firmin RL, Kukla M, MacLain VR, Buck B, Lysaker PH, Salyers MP. Lexical analysis in schizophrenia: how emotion and social word use informs our understanding of clinical presentation. Journal of psychiatric research. 2015 May 1; 64:74-8.
  51. Ganzini LK, Gross A. Cancer Care for Patients with Schizophrenia. In: Holland JC, Breitbart WS, Butow PN, Jacobsen PB, Loscalzo MJ, McCorkle R, editors. Psycho-Oncology. New York, NY: Oxford University Press; 2015. Chapter 44. 345-355 p.
  52. Predmore ZS, Mattke S, Horvitz-Lennon M. Improving antipsychotic adherence among patients with schizophrenia: savings for states. Psychiatric services (Washington, D.C.). 2015 Apr 1; 66(4):343-5.
  53. Kasckow JW. Pharmacologic and psychosocial treatments for the older patient with schizophrenia: the evidence base. Presented at: American Association for Geriatric Psychiatry Annual Meeting; 2015 Mar 28; New Orleans, LA.
  54. Ramage EM, Weintraub DM, Vogel SJ, Sutton GP, Ringdahl EN, Allen DN, Snyder JS. Preliminary evidence for reduced auditory lateral suppression in schizophrenia. Schizophrenia Research. 2015 Mar 1; 162(1-3):269-75.
  55. Kasckow J, Gao S, Hanusa B, Rotondi A, Chinman M, Zickmund S, Gurklis J, Fox L, Cornelius J, Richmond I, Haas GL. Telehealth Monitoring of Patients with Schizophrenia and Suicidal Ideation. Suicide & Life-Threatening Behavior. 2015 Oct 1; 45(5):600-611.
  56. Lysaker PH, Kukla M, Belanger E, White DA, Buck KD, Luther L, Firmin RL, Leonhardt B. Individual Psychotherapy and Changes in Self-Experience in Schizophrenia: A Qualitative Comparison of Patients in Metacognitively Focused and Supportive Psychotherapy. Psychiatry. 2015 Jan 1; 78(4):305-16.
  57. Mittal D, Corrigan P, Sherman MD, Chekuri L, Han X, Reaves C, Mukherjee S, Morris S, Sullivan G. Healthcare providers' attitudes toward persons with schizophrenia. Psychiatric Rehabilitation Journal. 2014 Dec 1; 37(4):297-303.
  58. Birgenheir DG, Ganoczy D, Bowersox NW. Service utilization among veterans with schizophrenia and a comorbid anxiety disorder. Psychiatric services (Washington, D.C.). 2014 Nov 1; 65(11):1354-9.
  59. Kasckow J, Rotondi A, Hanusa B, Zickmund S, Chinman M, Gao S, Haas G. Monitoring suicidal Veterans with schizophrenia using telehealth. Presented at: American Psychiatric Association Institute on Psychiatric Services Annual Conference; 2014 Nov 1; San Francisco, CA.
  60. Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, Guthrie S, Horvitz-Lennon M, Larivière V, Jones MM, Ni Chonaill S, O'Brien C, Olmsted SS, Schultz DJ, Winpenny E, Pincus HA, Grant J. Mental health retrosight: identifying the attributes of successfully translated research (lessons from schizophrenia) [RAND Corporation Research Brief]. 2014 Oct 28.
  61. Armstrong NP, Cohen AN, Hellemann G, Reist C, Young AS. Validating a brief version of the Mental Health Recovery Measure for individuals with schizophrenia. Psychiatric services (Washington, D.C.). 2014 Sep 1; 65(9):1154-9.
  62. Fontanella CA, Guada J, Phillips G, Ranbom L, Fortney JC. Individual and contextual-level factors associated with continuity of care for adults with schizophrenia. Administration and policy in mental health. 2014 Sep 1; 41(5):572-87.
  63. Kukla M, Davis LW, Lysaker PH. Cognitive behavioral therapy and work outcomes: correlates of treatment engagement and full and partial success in schizophrenia. Behavioural and cognitive psychotherapy. 2014 Sep 1; 42(5):577-92.
  64. Horvitz-Lennon M, Volya R, Donohue JM, Lave JR, Stein BD, Normand SL. Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008. Health services research. 2014 Aug 1; 49(4):1121-44.
  65. Kukla M, Lysaker PH, Roe D. Strong subjective recovery as a protective factor against the effects of positive symptoms on quality of life outcomes in schizophrenia. Comprehensive psychiatry. 2014 Aug 1; 55(6):1363-8.
  66. Lysaker P, Hillis J, Leonhardt BL, Kukla ME, Buck KD. Metacognition in schizophrenia spectrum disorders: Methods of assessment and associations with psychosocial function, neurocognition, symptoms, and cognitive style. In: Social cognition and metacognition in schizophrenia: Psychopathology and treatment approaches. San Diego, CA: Academic Press; 2014. Chapter 6. 99-110 p.
  67. Niv N, Cohen AN, Hamilton A, Reist C, Young AS. Effectiveness of a psychosocial weight management program for individuals with schizophrenia. The journal of behavioral health services & research. 2014 Jul 1; 41(3):370-80.
  68. Klingaman EA, Viverito KM, Medoff DR, Hoffmann RM, Goldberg RW. Strategies, barriers, and motivation for weight loss among veterans living with schizophrenia. Psychiatric Rehabilitation Journal. 2014 Dec 1; 37(4):270-6.
  69. Harvey PD, Siever LJ, Huang GD, Muralidhar S, Zhao H, Miller P, Aslan M, Mane S, McNamara M, Gleason T, Brophy M, Przygodszki R, O'Leary TJ, Gaziano M, Concato J. The genetics of functional disability in schizophrenia and bipolar illness: Methods and initial results for VA cooperative study #572. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2014 Jun 1; 165B(4):381-9.
  70. Cohen C, Kasckow JW. The emerging crisis in the care of older adults with schizophrenia: what can be done. Presented at: American Psychiatric Association Annual Workshop; 2014 May 5; New York, NY.
  71. Kasckow JW, Rotondi AJ, Hanusa BH, Fox L, Zickmund SL, Chinman MJ, Gao S, Haas GL. Telehealth monitoring in suicidal Veterans with schizophrenia. Poster session presented at: American Psychiatric Association Annual Meeting; 2014 May 5; New York, NY.
  72. Sanghani S, Kasckow JW, Golshan S, Zisook S. Antidepressant response in the treatment of subsyndromal depression in middle aged and older patients with schizophrenia. Poster session presented at: American Psychiatric Association Annual Meeting; 2014 May 5; New York, NY.
  73. Kasckow J, Golshan S, Zisook S. Does age moderate the relationship between depressive symptoms and suicidal ideation in middle-aged and older patients with schizophrenia and subthreshold depression? The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2014 May 1; 22(5):437-41.
  74. Kasckow J, Felmet K, Appelt C, Thompson R, Rotondi A, Haas G. Telepsychiatry in the assessment and treatment of schizophrenia. Clinical schizophrenia & related psychoses. 2014 Apr 1; 8(1):21-27A.
  75. Kasckow J, Zickmund S, Rotondi A, Mrkva A, Gurklis J, Chinman M, Fox L, Loganathan M, Hanusa B, Haas G. Development of telehealth dialogues for monitoring suicidal patients with schizophrenia: consumer feedback. Community mental health journal. 2014 Apr 1; 50(3):339-42.
  76. Kasckow JW, Zickmund SL, Walch A, Rotondi AJ, Chinman MJ, Fox L, Haas GL. Optimizing scripted dialogues for an e-health intervention for middle aged and older suicidal Veterans with schizophrenia. Paper presented at: American Association for Geriatric Psychiatry Annual Meeting; 2014 Mar 16; Orlando, FL.
  77. Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Research. 2013 Nov 30; 210(1):16-20.
  78. Birgenheir DG. Pain conditions among veterans with schizophrenia or bipolar disorder. Poster session presented at: Association for Behavioral and Cognitive Therapies Annual Convention; 2013 Nov 23; Nashville, TN.
  79. Kukla M, Lysaker PH, Salyers MP. Do persons with schizophrenia who have better metacognitive capacity also have a stronger subjective experience of recovery? Psychiatry Research. 2013 Oct 30; 209(3):381-5.
  80. Thwin SS, Hermes E, Lew R, Barnett P, Liang M, Valley D, Rosenheck R. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Research. 2013 Oct 30; 209(3):291-6.
  81. Xu ZY, Zu S, Xiang YT, Wang N, Guo ZH, Kilbourne AM, Brabban A, Kingdon D, Li ZJ. Associations of self-esteem, dysfunctional beliefs and coping style with depression in patients with schizophrenia: a preliminary survey. Psychiatry Research. 2013 Oct 30; 209(3):340-5.
  82. Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, Guthrie S, Horvitz-Lennon M, Larivière V, Jones MM, Ni Chonaill S, O'Brien C, Olmsted SS, Schultz D, Winpenny E, Pincus HA, Grant J. Mental health retrosight: understanding the returns from research (lessons from schizophrenia): policy report. Santa Monica, CA: RAND Corporation; 2013 Oct 28. 84 p. Report No.: RR-325-GBF.
  83. Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, Guthrie S, Horvitz-Lennon M, Larivière V, Jones MM, Ni Chonaill S, O'Brien C, Olmsted SS, Schultz DJ, Winpenny E, Pincus HA, Grant J. Mental health retrosight: identifying the attributes of successfully translated research (lessons from schizophrenia). (RAND Research Brief). 2013 Oct 28.
  84. Kasckow JW, Zickmund SL, Walch A, Rotondi AJ, Chinman MJ, Fox L, Haas GL. Optimizing scripted dialogues for an e-health intervention for suicidal Veterans with major depression or schizophrenia: a ‘user design’ approach. Poster session presented at: American Psychiatric Association Institute on Psychiatric Services Annual Conference; 2013 Oct 11; Philadelphia, PA.
  85. Birgenheir DG, Ilgen MA, Bohnert AS, Abraham KM, Bowersox NW, Austin K, Kilbourne AM. Pain conditions among veterans with schizophrenia or bipolar disorder. General hospital psychiatry. 2013 Sep 1; 35(5):480-4.
  86. Lysaker P, Bob P, Pec O, Hamm J, Kukla ME, Vohs J, Dimaggio G. Synthetic metacognition as a link between brain and behavior in schizophrenia. Translational neuroscience. 2013 Sep 1; 4(3):368-377.
  87. Salyers MP, Matthias MS, Sidenbender S, Green A. Patient activation in schizophrenia: insights from stories of illness and recovery. Administration and policy in mental health. 2013 Sep 1; 40(5):419-27.
  88. Hamm JA, Hasson-Ohayon I, Kukla M, Lysaker PH. Individual psychotherapy for schizophrenia: trends and developments in the wake of the recovery movement. Psychology research and behavior management. 2013 Aug 6; 6:45-54.
  89. Lysaker PH, Vohs J, Hasson-Ohayon I, Kukla M, Wierwille J, Dimaggio G. Depression and insight in schizophrenia: comparisons of levels of deficits in social cognition and metacognition and internalized stigma across three profiles. Schizophrenia Research. 2013 Aug 1; 148(1-3):18-23.
  90. Lysaker PH, Vohs J, Hillis JD, Kukla M, Popolo R, Salvatore G, Dimaggio G. Poor insight into schizophrenia: contributing factors, consequences and emerging treatment approaches. Expert Review of Neurotherapeutics. 2013 Jul 1; 13(7):785-93.
  91. Berges A, Ong M, Goldberg R. Schizophrenia. In: Ferri F, editor. Ferri’s Clinical Advisor 2014: 5 Books in 1. 2014 ed. Philadelphia, PA: Elsevier Mosby; 2013. 993-4 p.
  92. Gören JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatric services (Washington, D.C.). 2013 Jun 1; 64(6):527-33.
  93. Ganzini LK. Advances in Medical Care for Patients with Schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting; 2013 May 20; San Francisco, CA.
  94. Bromley E, Adams GF, Brekke JS. A video ethnography approach for linking naturalistic behaviors to research constructs of neurocognition in schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences. 2013 Apr 26; 24(2):125-40.
  95. Kasckow JW, Haas GL, Cornelius J, Luther J. Telehealth monitoring of suicidal ideation in patients with schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2013 Apr 23; Orlando, FL.
  96. Kukla ME, Lysaker P. Metacognition and the subjective experience of recovery in schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2013 Apr 21; Orlando, FL.
  97. Janney CA, Ganguli R, Richardson CR, Holleman RG, Tang G, Cauley JA, Kriska AM. Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study). Schizophrenia Research. 2013 Apr 1; 145(1-3):63-8.
  98. Kukla M, Salyers MP, Lysaker PH. Levels of patient activation among adults with schizophrenia: associations with hope, symptoms, medication adherence, and recovery attitudes. The Journal of nervous and mental disease. 2013 Apr 1; 201(4):339-44.
  99. Vahia IV, Lanouette NM, Golshan S, Fellows I, Mohamed S, Kasckow JW, Zisook S. Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms. Indian journal of psychiatry. 2013 Apr 1; 55(2):144-8.
  100. Kasckow JW, Luther J, Fox L, Loganathan M, Haas GL. Telehealth monitoring of older patients with schizophrenia at risk for suicide. Presented at: American Association for Geriatric Psychiatry Annual Meeting; 2013 Mar 15; Los Angeles, CA.
  101. Lysaker PH, Gumley A, Luedtke B, Buck KD, Ringer JM, Olesek K, Kukla M, Leonhardt BL, Popolo R, Dimaggio G. Social cognition and metacognition in schizophrenia: evidence of their independence and linkage with outcomes. Acta Psychiatrica Scandinavica. 2013 Mar 1; 127(3):239-47.
  102. Ganzini LK. Delirium and End of Life Care in Patients with Schizophrenia. Paper presented at: Academy of Psychosomatic Medicine Annual Meeting; 2012 Nov 17; Atlanta, GA.
  103. Kasckow J, Appelt C, Haas GL, Huegel S, Fox L, Gurklis J, Zickmund S, Daley D. Development of a recovery manual for suicidal patients with schizophrenia: consumer feedback. Community mental health journal. 2012 Oct 1; 48(5):564-7.
  104. Ganzini L, Mansoor D, Socherman R, Duckart J. Delirium and decisional incapacity in veterans with schizophrenia and medical illness. General hospital psychiatry. 2012 Sep 1; 34(5):506-9.
  105. Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? Neuropsychobiology. 2012 Aug 27; 65(3):168-72.
  106. Owen RR, Hudson TJ, Thrush CR, Williams DK, Armitage TL. An Intervention to Implement Medication Management Recommendations of Schizophrenia Guidelines. Paper presented at: VA HSR&D / QUERI National Meeting; 2012 Jul 19; National Harbor, MD.
  107. Morden NE, Lai Z, Goodrich DE, MacKenzie T, McCarthy JF, Austin K, Welsh DE, Bartels S, Kilbourne AM. Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. General hospital psychiatry. 2012 Jul 1; 34(4):368-79.
  108. Doshi J, Li P, McElligott S, Sen A, Olfson M, Pauly M, Polsky D, Rosenheck R, Marcus SC. The effects of cost-sharing on antipsychotic medication use in dual eligibles with schizophrenia: implications for state policies on copayment assistance under Medicare Part D. Paper presented at: AcademyHealth Annual Research Meeting; 2012 Jun 25; Orlando, FL.
  109. Kasckow J, Mrkva A, Rotondi A, Chinman M, Fox L, Loganathan M, Haas G, Zickmund S. Optimizing scripted dialogues for an e-health intervention for suicidal Veterans with schizophrenia: a “user design” approach using qualitative methods. Poster session presented at: VA / Department of Defense Suicide Prevention Annual Conference; 2012 Jun 20; Washington, DC.
  110. Kasckow J, Liu N, Phillips MR. Case-control study of the relationship of functioning to suicide in a community-based sample of individuals with schizophrenia in China. Community mental health journal. 2012 Jun 1; 48(3):317-20.
  111. Barnett PG, Scott JY, Krystal JH, Rosenheck RA, CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal of clinical psychiatry. 2012 May 1; 73(5):696-702.
  112. Kasckow JW, Golshan S, Zisook S. Subsyndromal depressive symptoms in middle aged and older patients with schizophrenia: relationship to suicidal ideation. Paper presented at: American Association for Geriatric Psychiatry Annual Meeting; 2012 Mar 18; Washington, DC.
  113. Bromley E. The texture of the real: experimentation and experience in schizophrenia. Culture, Medicine and Psychiatry. 2012 Mar 1; 36(1):154-74.
  114. Davis CL, Kilbourne AM, Blow FC, Pierce JR, Winkel BM, Huycke E, Langberg R, Lyle D, Phillips Y, Visnic S. Reduced mortality among Department of Veterans Affairs patients with schizophrenia or bipolar disorder lost to follow-up and engaged in active outreach to return for care. American journal of public health. 2012 Mar 1; 102 Suppl 1:S74-9.
  115. Outcalt SD, Lysaker PH. The relationships between trauma history, trait anger, and stigma in persons diagnosed with schizophrenia spectrum disorders. Psychosis. 2012 Feb 9; 4(1):32-41.
  116. Herrold AA, Napier TC. Role of mGluR5 in stimulant addiction, schizophrenia co-morbidity, and neurogenesis. In: Olive MF, editor. Drug Addiction & Adult Neurogenesis. Karala, India: Research Signpost/Transworld Research Network Publishers; 2011. Chapter 3. 41-68 p.
  117. Rotondi AJ. Effectiveness of web-based family psychoeducational therapy delivered to the homes of persons with schizophrenia and their family members. Paper presented at: Institute on Psychiatric Services Annual Meeting; 2011 Oct 27; San Francisco, CA.
  118. Olfson M, Ascher-Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatric services (Washington, D.C.). 2011 Oct 1; 62(10):1138-45.
  119. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 2011 Sep 15; 191:78-90.
  120. Kasckow JW, Appelt C, Felmet K, Daley D, Haas G. Development a coping manual for Veterans with schizophrenia and suicidal behaviors: qualitative findings. Paper presented at: VA Mental Health Annual Conference; 2011 Aug 25; Baltimore, MD.
  121. Barnett PG, Scott JY, Rosenheck RA, CSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia? Schizophrenia Research. 2011 Aug 1; 130(1-3):34-9.
  122. Farley JF, Wang CC, Hansen RA, Voils CI, Maciejewski ML. Continuity of antipsychotic medication management for Medicaid patients with schizophrenia. Psychiatric services (Washington, D.C.). 2011 Jul 1; 62(7):747-52.
  123. Rost K, Hsieh YP, Xu S, Menachemi N, Young AS. Potential disparities in the management of schizophrenia in the United States. Psychiatric services (Washington, D.C.). 2011 Jun 1; 62(6):613-8.
  124. Kasckow JW, Liu N, Phillips M. Case-control study of the relationship of functioning to suicide in a community-based sample of individuals with schizophrenia in China. Paper presented at: American Psychiatric Association Annual Meeting; 2011 May 16; Honolulu, HI.
  125. Copeland LA, Zeber JE, Sako EY, Flynn J, MacCarthy A, MacCarthy D, Lawrence VA. Epidemiology of Three Common Surgeries in Veterans with Schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2011 Apr 3; Colorado Springs, CO.
  126. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH, CSP 555 Research Group. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clinical trials (London, England). 2011 Apr 1; 8(2):196-204.
  127. Kasckow JW, Haas G, Appelt C, Daley D, Felmet K, Haas G. Development of a coping manual for individuals with schizophrenia and suicidal behaviors. Paper presented at: VA / Department of Defense Suicide Prevention Annual Conference; 2011 Mar 16; Boston, MA.
  128. Kasckow JW, Haas G, Gurklis J. A telehealth intervention for suicidal Veterans with schizophrenia. Paper presented at: VA / Department of Defense Suicide Prevention Annual Conference; 2011 Mar 16; Boston, MA.
  129. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH, CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. The New England journal of medicine. 2011 Mar 3; 364(9):842-51.
  130. Lysaker PH, Davis LW, Buck KD, Outcalt S, Ringer JM. Negative symptoms and poor insight as predictors of the similarity between client and therapist ratings of therapeutic alliance in cognitive behavior therapy for patients with schizophrenia. The Journal of nervous and mental disease. 2011 Mar 1; 199(3):191-5.
  131. Zeber JE, Copeland LA, Lawrence VA, Pugh MJ, Restrepo MI. Surgical Rates of common procedures in Veterans with Schizophrenia and Other Mental Illness. [Abstract]. Schizophrenia Bulletin. 2011 Mar 1; 37(S1):101-101.
  132. Zeber JE, Copeland LA, Miller AL, Valenstein M, Leykum L. Cost-Benefit Analysis of Higher medication Copayments in Veterans with Schizophrenia. [Abstract]. Journal of Mental Health Policy and Economics. 2011 Mar 1; 14(S1):S39-S39.
  133. Cohen AN, Young AS, Hamilton A, Teague A, Mullins D, Chemerinski E, Schubert M, Steele A, DeBakey E, McNagny K, Reist C. Returning Veterans with Schizophrenia to Paid, Competitive Employment. Poster session presented at: VA HSR&D National Meeting; 2011 Feb 16; National Harbor, MD.
  134. Felmet K, Zisook S, Kasckow JW. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clinical schizophrenia & related psychoses. 2011 Jan 1; 4(4):239-50.
  135. Osatuke K, Reid M, Stiles WB, Kasckow JW, Zisook S, Mohamed S. Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia. Psychotherapy research : journal of the Society for Psychotherapy Research. 2011 Jan 1; 21(1):41-53.
  136. Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. Schizophrenia Research. 2010 Dec 1; 124(1-3):1-12.
  137. Copeland LA, Parchman ML, Zeber JE, Lawrence VA, Downs JR, Miller AL. Prediabetes assessment and follow-up in older veterans with schizophrenia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2010 Oct 1; 18(10):887-96.
  138. Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community mental health journal. 2011 Apr 1; 47(2):123-35.
  139. Hamilton A, Cohen AN, Young AS. Women with Schizophrenia Who Use Outpatient VA Clinics. Poster session presented at: VA HSR&D Field-Based Women's Health Meeting; 2010 Jul 14; Arlington, VA.
  140. Ganzini L, Socherman R, Duckart J, Shores M. End-of-life care for veterans with schizophrenia and cancer. Psychiatric services (Washington, D.C.). 2010 Jul 1; 61(7):725-8.
  141. Olfson M, Marcus SC, Doshi JA. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. The Journal of clinical psychiatry. 2010 Jul 1; 71(7):831-8.
  142. Salyers MP. Coping with positive and negative symptoms of schizophrenia. American Journal of Psychiatric Rehabilitation. 2010 Jul 1; 13(1):208-223.
  143. Young AS, Niv N, Cohen AN, Kessler C, McNagny K. The appropriateness of routine medication treatment for schizophrenia. Schizophrenia Bulletin. 2010 Jul 1; 36(4):732-9.
  144. Ganzini LK. End of Life Care for Patients with Cancer and Schizophrenia. Poster session presented at: VA HSR&D Field-Based Mental Health and Substance Use Disorders Meeting; 2010 Apr 28; Little Rock, AR.
  145. Copeland LA, Zeber JE, Parchman ML, Downs JR, Miller AL, Lawrence VA. Prediabetes Assessment and Follow-up in Older Veterans with Schizophrenia. Poster session presented at: VA HSR&D Field-Based Mental Health and Substance Use Disorders Meeting; 2010 Apr 27; Little Rock, AR.
  146. Long ME, Grubaugh AL, Elhai JD, Cusack KJ, Knapp R, Frueh BC. Therapist fidelity with an exposure-based treatment of PTSD in adults with schizophrenia or schizoaffective disorder. Journal of Clinical Psychology. 2010 Apr 1; 66(4):383-93.
  147. Young AS, Hamilton A, Cohen AN. Evaluating Implementation of Evidence-Based Care for Schizophrenia. Paper presented at: National Institutes of Health Conference on the Science of Dissemination and Implementation: Methods and Measurement; 2010 Mar 15; Bethesda, MD.
  148. Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophrenia Bulletin. 2010 Mar 1; 36(2):428-35.
  149. Cohen AN, Glynn SM, Hamilton AB, Young AS. Implementation of a family intervention for individuals with schizophrenia. Journal of general internal medicine. 2010 Jan 1; 25 Suppl 1:32-7.
  150. Ganzini L, Socherman R. Cancer Care for Patients with Schizophrenia. In: Holland JC, editor. Psycho-oncology. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2010. Chapter 49. 363-368 p.
  151. Rapp MA, Schnaider-Beeri M, Purohit DP, Reichenberg A, McGurk SR, Haroutunian V, Harvey PD. Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. Schizophrenia Research. 2010 Jan 1; 116(1):90-6.
  152. Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang XY. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology. 2009 Dec 1; 207(3):375-80.
  153. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. The Psychiatric quarterly. 2009 Dec 1; 80(4):241-9.
  154. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2009 Nov 13; 33(8):1508-12.
  155. Rotondi AJ. Schizophrenia. In: Cucciare MA, Weingardt KR, editors. Using Technology to Support Evidence-based Behavioral Health Practices - A Clinician's Guide. New York, NY: Taylor and Francis Group; 2009. Chapter 4. 69-90 p.
  156. Shim R, Rust G, Sambamoorthi U. Schizophrenia and Diabetes: A High Impact Comorbidity Cluster. Poster session presented at: Disease Management Association of America Care Continuum Alliance Annual Forum; 2009 Sep 21; San Diego, CA.
  157. Copeland LA, Zeber JE, Wang CP, Parchman ML, Lawrence VA, Valenstein M, Miller AL. Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilization. BMC health services research. 2009 Jul 26; 9:127.
  158. Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009 Jul 1; 34(8):1885-903.
  159. Zeber JE, Copeland LA, Miller AL, Valenstein M, Leykum L. A cost-benefit analysis of higher medication copayments in veterans with schizophrenia. Poster session presented at: AcademyHealth Annual Research Meeting; 2009 Jun 28; Chicago, IL.
  160. Fortney JC, Xu S, Dong F. Community-level correlates of hospitalizations for persons with schizophrenia. Psychiatric services (Washington, D.C.). 2009 Jun 1; 60(6):772-8.
  161. Frueh BC, Grubaugh AL, Cusack KJ, Kimble MO, Elhai JD, Knapp RG. Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study. Journal of anxiety disorders. 2009 Jun 1; 23(5):665-75.
  162. Copeland LA, Miller AL, Lawrence VA, Hosek B, Parchman ML, Zeber JE. Pre-diabetes and diabetes assessment in veterans with schizophrenia. Paper presented at: International Congress on Schizophrenia Research; 2009 Mar 28; San Diego, CA.
  163. Zeber JE, Copeland LA, Miller AL, Valenstein M, Leykum L. A cost-benefit analysis of higher medication copayments in veterans with schizophrenia. Paper presented at: International Congress on Schizophrenia Research; 2009 Mar 28; San Diego, CA.
  164. Frueh BC, Grubaugh AL, Cusack KJ, Kimble MO, Elhai JD, Knapp RG. Exposure-based cognitive behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder. Poster session presented at: Anxiety Disorders Association of America Annual Conference; 2009 Mar 15; Santa Ana Pueblo, NM.
  165. Zeber J, Copeland L, Miller A, Valenstein MT, Leykum L. A cost-benefit analysis of higher medication copayments in veterans with schizophrenia. Presented at: VA HSR&D National Meeting; 2009 Feb 11; Baltimore, MD.
  166. Young AS, Brown AH, Cohen AN, Chinman MJ, Reist C. Implementing Treatment Guidelines in Schizophrenia: Process Evaluation of Implementation in EQUIP. Poster session presented at: VA QUERI National Meeting; 2008 Dec 8; Phoenix, AZ.
  167. Long ME, Grubaugh AL, Elhai JD, Knapp RG, Frueh BC. Therapist fidelity with an exposure-based treatment of PTSD in adults with Schizophrenia or Schizoaffective Disorder. Poster session presented at: Association for Behavioral and Cognitive Therapies Annual Convention; 2008 Nov 15; Orlando, FL.
  168. Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. Journal of psychiatric research. 2008 Oct 1; 42(13):1076-85.
  169. Fischer EP, McCarthy JF, Ignacio RV, Blow FC, Barry KL, Hudson TJ, Owen RR, Valenstein M. Longitudinal patterns of health system retention among veterans with schizophrenia or bipolar disorder. Community mental health journal. 2008 Oct 1; 44(5):321-30.
  170. Fischer EP, McSweeney JC, Pyne JM, Williams DK, Naylor AJ, Blow FC, Owen RR. Family Involvement Modifies the Effect of Substance Use on Sustained Utilization of Services for Schizophrenia. Paper presented at: National Association for Rural Mental Health Annual Conference; 2008 Aug 8; Burlington, VT.
  171. Fischer EP, McSweeney JC, Pyne JM, Williams DK, Naylor AJ, Blow FC, Owen RR. Influence of family involvement and substance use on sustained utilization of services for schizophrenia. Psychiatric services (Washington, D.C.). 2008 Aug 1; 59(8):902-8.
  172. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, Li J, Lu L, Kosten TA, Kosten TR. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008 Aug 1; 33(9):2200-5.
  173. Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY. Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neuroscience Letters. 2008 Jul 25; 440(1):35-7.
  174. Cohen AN, Young AS, Hamilton-Brown A, Chinman MJ, Henderson C, Thomesen C, Hamilton JD, Teague A, Robinson D, Hicks P, Widmark C, Reist C. Evaluating Challenges and Facilitators to Improving Care for Schizophrenia: EQUIP-2 Results at Eight VA Medical Centers. Paper presented at: VA MIRECC Annual Best Practices in Mental Health Conference; 2008 Jul 22; Arlington, VA.
  175. Young AS, Hamilton-Brown A, Chinman MJ, Cohen AN, Reist C. Improving Care for Schizophrenia: Process Evaluation of Implementation in EQUIP. Poster session presented at: VA MIRECC Annual Best Practices in Mental Health Conference; 2008 Jul 22; Arlington, VA.
  176. Owen RR, Hudson T, Thrush C, Thapa P, Armitage T, Landes RD. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. Medical care. 2008 Jul 1; 46(7):686-91.
  177. Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY. Association between interleukin-6 receptor polymorphism and patients with schizophrenia. Schizophrenia Research. 2008 Jul 1; 102(1-3):346-7.
  178. Smith JL, Spollen JJ, Owen RR. Facilitation in Implementing Evidence-Based Practices for Schizophrenia: Researcher & Clinical Leader Perspectives. Paper presented at: University of Alberta Knowledge Translation Annual Forum; 2008 Jun 12; Alberta, Canada.
  179. Owen RR, Smith JL, Hudson TJ, Curran GM. Comparison of Strategies to Improve Antipsychotic Monitoring and Management for Schizophrenia. Poster session presented at: AcademyHealth Annual Research Meeting; 2008 Jun 8; Washington, DC.
  180. Parchman ML, Copeland L, Zeber J, Hosek B, Lawrence V. Identifying pre-diabetes among veterans with schizophrenia. Poster session presented at: AcademyHealth Annual Research Meeting; 2008 Jun 1; Washington, DC.
  181. Zeber JE, Copeland LA, Miller AL, Kilbourne AM, Velligan DI, Mortensen EM. Ethnicity and the impact of higher medication copayments among veterans with schizophrenia. Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2008 May 3; Toronto, Canada.
  182. Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YW, Castillo D, Miller AL. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophrenia Bulletin. 2008 May 1; 34(3):483-93.
  183. Zeber JE, Valenstein M, Miller AL, Stensland M. The cost-offset effect of a copayment increase among veterans with schizophrenia. Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2008 May 1; Toronto, Canada.
  184. Allwine R, Eon S, Zillich AJ, Ott C. Rates of Adherence to Antipsychotic Medications in a Population of Patients with Bipolar Disorder or Schizophrenia in a Community Mental Health Setting: Evaluation of 60-Day Refill Data. Presented at: College of Psychiatric and Neurologic Pharmacists Annual Meeting; 2008 Apr 13; Scottsdale, AZ.
  185. Pyne JM, Labbate C. Ranking of outcome domains for use in real-time outcomes feedback laboratory by patients with schizophrenia. The Journal of nervous and mental disease. 2008 Apr 1; 196(4):336-9.
  186. Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The journal of behavioral health services & research. 2008 Apr 1; 35(2):215-25.
  187. Zeber JE, Copeland LA, Miller AL, Kilbourne AM, Velligan DI, Mortensen EM. Ethnicity and the impact of higher medication copayments among patients with schizophrenia. Poster session presented at: RWJ Foundation Critical Research Issues in Latino Mental Health Annual Conference; 2008 Mar 10; Santa Fe, NM.
  188. Brown AH, Cohen AN, Chinman MJ, Kessler C, Young AS. EQUIP: implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series. Implementation science : IS. 2008 Feb 15; 3:9.
  189. Young AS, Niv N, Cohen AN, Kessler C, McNagny K. The Quality of Medication Management for Schizophrenia: An Update. Presented at: VA HSR&D National Meeting; 2008 Feb 14; Baltimore, MD.
  190. Kreyenbuhl JK, Dixon LB, McCarthy JF, Soliman SS, Valenstein M. Adherence to Oral Hypoglycemic Medications among VA Patients with Schizophrenia and Type 2 Diabetes. Presented at: VA HSR&D National Meeting; 2008 Feb 13; Baltimore, MD.
  191. Owen RR, Smith JL, Hudson TJ, Curran GM. Comparison of Strategies to Improve Antipsychotic Monitoring and Management for Schizophrenia. Paper presented at: VA HSR&D National Meeting; 2008 Feb 13; Baltimore, MD.
  192. Young AS, Hamilton A, Cohen AN, Chinman MJ, Kessler C. Improving Care for Schizophrenia: Process Evaluation of Implementation in EQUIP. Presented at: VA HSR&D National Meeting; 2008 Feb 13; Baltimore, MD.
  193. Young AS, Niv N, Cohen AN, Mintz J, Ventura J. The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Poster session presented at: VA HSR&D National Meeting; 2008 Feb 12; Baltimore, MD.
  194. Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, Meyer WJ. Adjunct extended-release valproate semisodium in late life schizophrenia. International journal of geriatric psychiatry. 2008 Feb 1; 23(2):142-7.
  195. Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. The Journal of clinical psychiatry. 2008 Jan 1; 69(1):74-80.
  196. Lysaker PH, Salyers MP, Tsai J, Spurrier LY, Davis LW. Clinical and psychological correlates of two domains of hopelessness in schizophrenia. Journal of rehabilitation research and development. 2008 Jan 1; 45(6):911-9.
  197. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008 Jan 1; 22(11):903-16.
  198. Li W, Wei J, Zhou DF, Tan YL, Cao YL, Zhang XY, Wu G, Kosten TA, Kosten TR. Lack of association between the BDNF C270T polymorphism and schizophrenia in a Chinese Han population. Schizophrenia Research. 2007 Dec 1; 97(1-3):297-8.
  199. Owen, Curtis. Improving Care for Schizophrenia. 2007 Dec 1; EQUIP Education Tool.
  200. Wang ZR, Zhou DF, Cao LY, Tan YL, Zhang XY, Li J, Lu L, Wu GY, Kosten TA, Kosten TR. Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia. Schizophrenia Research. 2007 Dec 1; 97(1-3):299-301.
  201. Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatrica Scandinavica. 2007 Oct 1; 116(4):290-8.
  202. Kilbourne AM, Brar JS, Drayer RA, Xu X, Post EP. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics. 2007 Sep 1; 48(5):412-7.
  203. Young AS. Implementing Recovery-Oriented, Evidence-Based Practices in Schizophrenia. Paper presented at: VA MIRECC Annual Best Practices in Mental Health Conference; 2007 Jul 19; Alexandria, VA.
  204. Smith JL, Spollen JJ, Owen RR. Facilitation in Implementing Evidence-Based Practices for Schizophrenia: Researcher & Clinical Leader Perspectives. Presented at: VA Transforming Mental Health Care Conference; 2007 Jul 18; Alexandria, VA.
  205. Smith JL, Spollen JJ, Owen RR. Facilitation in Implementing Evidence-Based Practices of Schizophrenia: Researcher & Clinical Leader Perspectives. Presented at: AcademyHealth Annual Research Meeting; 2007 Jun 3; Orlando, FL.
  206. Hudson TJ. Schizophrenia. In: PharmPrep 3rd Edition: Case-Based Board Review. AMerican Society of Health-systems pharmacists; 2007. 280-285 p.
  207. Zeber JE, Grazier KL, Valenstein M, Blow FC, Lantz PM. Effect of a medication copayment increase in veterans with schizophrenia. The American journal of managed care. 2007 Jun 1; 13(6 Pt 2):335-46.
  208. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. Journal of the American Pharmacists Association : JAPhA. 2007 May 1; 47(3):373-8.
  209. Copeland LA, Mortensen EM, Zeber JE, Pugh MJ, Restrepo MI, Dalack GW. Pulmonary disease among inpatient decedents: Impact of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007 Apr 13; 31(3):720-6.
  210. Garman PM, Ried LD, Bengston MA, Hsu C. Monitoring Glucose Regulation Parameters in Veterans Living with Schizophrenia-Related Disorders and Switched from One Second-Generation Antipsychotic to Another. Poster session presented at: Academy of Managed Care Pharmacy Annual Meeting; 2007 Apr 13; San Diego, CA.
  211. Copeland LA, Lawrence VA, Zeber JE, Mortensen, EM. Surgery rates among veterans with schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2007 Mar 28; Colorado Springs, CO.
  212. Zeber JE, Copeland LA, Mortensen EM, Pugh MJ, Restrepo M, Dalack G. Impact of schizophrenia on pulmonary disease among impatient descendants. Poster session presented at: International Congress on Schizophrenia Research; 2007 Mar 28; Colorado Springs, CO.
  213. Ried LD. Lipid Profile Monitoring In Veterans Living With Schizophrenia-Related Disorders And Treated With Second-Generation Antipsychotics: Findings From A VA-Based Population. Poster session presented at: American Pharmaceutical Association Annual Meeting; 2007 Mar 17; Atlanta, GA.
  214. Calhoun PS, Stechuchak KM, Strauss J, Bosworth HB, Marx CE, Butterfield MI. Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia. Schizophrenia Research. 2007 Mar 1; 91(1-3):210-6.
  215. Copeland LA. First year of the VA HSR&D career development award: Patterns of late-life healthcare among VA patients with schizophrenia. Paper presented at: VA HSR&D National Meeting; 2007 Feb 21; Arlington, VA.
  216. Niv N, Cohen AN, Mintz J, Ventura J, Young AS. The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophrenia Research. 2007 Feb 1; 90(1-3):245-250.
  217. Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatric services (Washington, D.C.). 2007 Feb 1; 58(2):207-12.
  218. Glynn SM, Cohen AN, Niv N. New challenges in family interventions for schizophrenia. Expert Review of Neurotherapeutics. 2007 Jan 1; 7(1):33-43.
  219. Yanos PT, Moos RH. Determinants of functioning and well-being among individuals with schizophrenia: an integrated model. Clinical Psychology Review. 2007 Jan 1; 27(1):58-77.
  220. Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. Journal of Clinical Psychopharmacology. 2006 Dec 1; 26(6):666-7.
  221. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. Journal of general internal medicine. 2006 Nov 1; 21(11):1133-7.
  222. Carney P, Jones E. A Controlled Study of Medical Comorbidity In Women and men with Schizophrenia and Schizoaffective Disorder. Journal of general internal medicine. 2006 Nov 1; 21(11):A-10-A-10.
  223. Walkup J, Wei W, Sambamoorthi U, Crystal S, Yanos P. Provision of Psychotherapy for a Statewide Population of Medicaid Beneficiaries With Schizophrenia. Psychological Services. 2006 Nov 1; 3(4):227-238.
  224. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychological medicine. 2006 Nov 1; 36(11):1535-40.
  225. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. American journal of epidemiology. 2006 Oct 1; 164(7):672-81.
  226. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. The Journal of clinical psychiatry. 2006 Oct 1; 67(10):1542-50.
  227. Cohen AN, Kessler C, McNagny K, Reist C, Mintz J, Young AS. EQUIP: Improving care for schizophrenia. Paper presented at: VA Best Practices Annual Symposium; 2006 Sep 1; Portland, OR.
  228. Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. The Journal of clinical psychiatry. 2006 Sep 1; 67(9):1323-6.
  229. Young AS, Cohen AN, Kessler C, McNagny K, Reist C, Mintz J. Implementing best practices to improve care for schizophrenia (EQUIP). Paper presented at: VA MIRECC Annual Best Practices in Mental Health Conference; 2006 Sep 1; Portland, OR.
  230. Pyne JM, McSweeney J, Kane HS, Harvey S, Bragg L, Fischer E. Agreement between patients with schizophrenia and providers on factors of antipsychotic medication adherence. Psychiatric services (Washington, D.C.). 2006 Aug 1; 57(8):1170-8.
  231. Compton MT, Esterberg ML, Druss BG, Walker EF, Kaslow NJ. A descriptive study of pathways to care among hospitalized urban African American first-episode schizophrenia-spectrum patients. Social psychiatry and psychiatric epidemiology. 2006 Jul 1; 41(7):566-73.
  232. McCarthy JF, Kales HC, Sajatovic M, Jeste DV, Ignacio R, Blow FC. New-Onset Schizophrenia Among Veterans: Prevalence and Patient Characteristics. Paper presented at: AcademyHealth Annual Research Meeting; 2006 Jun 25; Seattle, WA.
  233. Calhoun PS, Bosworth HB, Stechuchak KA, Strauss J, Butterfield MI. The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia. Journal of traumatic stress. 2006 Jun 1; 19(3):393-7.
  234. Cohen AN, Glynn S, Brown AH, Young AS. Involving families in the care of patients with schizophrenia: Patient and provider barriers. Paper presented at: AcademyHealth Annual Research Meeting; 2006 Jun 1; Seattle, WA.
  235. Cohen AN, Young AS. EQUIP: Evaluating a chronic illness care model for schizophrenia. Paper presented at: AcademyHealth Annual Research Meeting; 2006 Jun 1; Seattle, WA.
  236. Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006 Jun 1; 31(6):1249-63.
  237. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research. 2006 May 1; 84(1):90-9.
  238. Mittal D, Davis CE, Depp C, Pyne JM, Golshan S, Patterson TL, Jeste DV. Correlates of health-related quality of well-being in older patients with schizophrenia. The Journal of nervous and mental disease. 2006 May 1; 194(5):335-40.
  239. Strauss JL, Calhoun PS, Marx CE, Stechuchak KM, Oddone EZ, Swartz MS, Butterfield MI. Comorbid posttraumatic stress disorder is associated with suicidality in male veterans with schizophrenia or schizoaffective disorder. Schizophrenia Research. 2006 May 1; 84(1):165-9.
  240. McCarthy JF, Kales HC, Sajatovic M, Jeste DV, Ignacio R, Blow FC. New-Onset Schizophrenia Among Veterans: Prevalence and Patient Characteristics. Paper presented at: American Association for Geriatric Psychiatry Annual Meeting; 2006 Mar 12; San Juan, Puerto Rico.
  241. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Molecular Psychiatry. 2006 Mar 1; 11(3):241-51.
  242. Sajatovic M, Friedman SH, Schuermeyer IN, Safavi R, Ignacio RV, Hays RW, West JA, Blow FC. Menopause knowledge and subjective experience among peri- and postmenopausal women with bipolar disorder, schizophrenia and major depression. The Journal of nervous and mental disease. 2006 Mar 1; 194(3):173-8.
  243. Zeber J, Copeland LA, Xu X, Miller A, Kilbourne AM, Velligan D, Mortensen E. Ethnicity and the impact of higher medication copayments among veterans with schizophrenia. Poster session presented at: VA HSR&D National Meeting; 2006 Feb 16; Arlington, VA.
  244. Valenstein M, Ganoczy D, McCarthy J, Blow FC, Kim M, Lee T. The Stability of Medication Adherence Among Patients with Schizophrenia. Paper presented at: VA HSR&D National Meeting; 2006 Feb 15; Arlington, VA.
  245. Burke RE, Walsh J, Matzilevich D, Benes FM. Mapping of hippocampal gene clusters regulated by the amygdala to nonlinkage sites for schizophrenia. Molecular Psychiatry. 2006 Feb 1; 11(2):158-71.
  246. Copeland LA, Zeber JE, Rosenheck RA, Miller AL. Unforeseen inpatient mortality among veterans with schizophrenia. Medical care. 2006 Feb 1; 44(2):110-6.
  247. Ren XS, Qian S, Lee AF, Herz L, Miller DR, Kazis LE. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. Journal of clinical pharmacy and therapeutics. 2006 Feb 1; 31(1):57-65.
  248. Young AS, Cohen AN, Mintz J. Evaluating a chronic care model designed to improve treatment for schizophrenia (EQUIP). Paper presented at: VA HSR&D National Meeting; 2006 Feb 1; Arlington, VA.
  249. Petrakis IL, Leslie D, Finney JW, Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2006 Jan 1; 15(1):44-9.
  250. Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. Pharmacoeconomics. 2006 Jan 1; 24(12):1233-48.
  251. Ren XS, Qian S, Lee AF. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2005 Nov 6; Florence, Italy.
  252. Ren XS, Kazis LE, Lee AF, Huang YH, Hamed A, Cunningham F, Herz L, Miller DR. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. Schizophrenia Research. 2005 Sep 15; 77(2-3):167-77.
  253. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of psychiatric practice. 2005 Sep 1; 11(5):315-39.
  254. Cohen AN, Young AS, Mintz J. Evaluating an Intervention to improve the quality of care in schizophrenia. Paper presented at: AcademyHealth Annual Research Meeting; 2005 Jun 1; Boston, MA.
  255. Owen RR, Smith JL, Young AS. Mental Health QUERI: Improving Treatment for Schizophrenia. Paper presented at: VA MIRECC Annual Conference; 2005 Jun 1; New Orleans, LA.
  256. Young AS, Cohen AN, Mintz J. Information systems and improving care for schizophrenia. Paper presented at: AcademyHealth Annual Research Meeting; 2005 Jun 1; Boston, MA.
  257. Butterfield MI, Zervakis J, Strauss J, Lieberman J, Marx CE. Neuroactive Steroids and Suicidality in Schizophrenia and Schizoaffective Disorder. Poster session presented at: American Psychiatric Association Annual Meeting; 2005 May 15; Atlanta, GA.
  258. Blow FC, McCarthy JF, Valenstein M, Smelson D, Reist C. Use of Atypical Antipsychotics Among VA patients with Schizophrenia: National Trends. Poster session presented at: International Congress on Schizophrenia Research; 2005 Apr 1; Savannah, GA.
  259. Fischer EP, McSweeney JC, Pyne JM, Yates T. Veteran's views on sustaining involvement in care for schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2005 Apr 1; Savannah, GA.
  260. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Patterns of combination antipsychotic treatment for veterans with schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2005 Apr 1; Savannah, GA.
  261. Owen RR, Hudson TJ, Thrush CR, Williams DK, Armitage TL, Thapa PB. An intervention to implement recommendations of schizophrenia guidelines. Paper presented at: International Congress on Schizophrenia Research; 2005 Apr 1; Savannah, GA.
  262. Zeber J, Grazier KL, Blow FC, Valenstein M, Lantz PM. The effect of a medication co-payment increase on veterans with schizophrenia. Poster session presented at: International Congress on Schizophrenia Research; 2005 Apr 1; Savannah, GA.
  263. Mittal D, Davis CE, Depp C, Pyne JM, Golshan S, Patterson LT, Jeste VD. Predictors of Health-Related Quality of Well-Being in Older Patients with Schizophrenia. Paper presented at: American Association for Geriatric Psychiatry Annual Meeting; 2005 Mar 15; San Diego, CA.
  264. Russo PA, Smith MW, Namjoshi M. Health care costs for schizophrenia patients started on olanzapine versus risperidone. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2005 Mar 15; 62(6):610-5.
  265. Ren XS, Huang YH, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. Journal of clinical pharmacy and therapeutics. 2005 Feb 1; 30(1):65-71.
  266. Bagchi A, Sambamoorthi U, McSpiritt E, Yanos P, Walkup J, Crystal S. Use of antipsychotic medications among HIV-infected individuals with schizophrenia. Schizophrenia Research. 2004 Dec 1; 71(2-3):435-44.
  267. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research. 2004 Dec 1; 71(2-3):239-48.
  268. Owen RR, Thrush CR, Cannon D, Sloan KL, Curran G, Hudson T, Austen M, Ritchie M. Use of electronic medical record data for quality improvement in schizophrenia treatment. Journal of the American Medical Informatics Association : JAMIA. 2004 Sep 1; 11(5):351-7.
  269. Young AS, Mintz J, Cohen AN, Chinman MJ. A network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT). Journal of the American Medical Informatics Association : JAMIA. 2004 Sep 1; 11(5):358-67.
  270. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. The American journal of psychiatry. 2004 Aug 1; 161(8):1334-49.
  271. Young AS, Cohen AN, Chinman MJ, Mintz J. Informatics to Improve Care for Schizophrenia. Paper presented at: VA Information Technology Annual Conference; 2004 Aug 1; Austin, TX.
  272. Costanzo ES, Antes LM, Christensen AJ. Behavioral and medical treatment of chronic polydipsia in a patient with schizophrenia and diabetes insipidus. Psychosomatic medicine. 2004 May 1; 66(2):283-6.
  273. Strauss JL, Calhoun PS, Marx CE, Butterfield MI. Comorbid PTSD linked to suicidality among veterans with schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting; 2004 May 1; New York, NY.
  274. Zeber J, Copeland L, Blow F, Smelson D. Atypical Antipsychotics and Schizophrenia with Comorbid Substance Abuse. Paper presented at: American Psychiatric Association Annual Meeting; 2004 May 1; New York, NY.
  275. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin. 2004 Apr 1; 30(2):255-64.
  276. Grabowski J, Schraner P, Valenstein M, Woltmann E, Kavanagh J, Zeber J. VA Administrative Diagnoses of Schizophrenia Versus Chart Diagnoses. Paper presented at: VA HSR&D National Meeting; 2004 Mar 1; Washington, DC.
  277. Pyne JM, McSweeney J, Fischer EP, Spence R, Bragg LA, Johnson-Turner T. Qualitative Approach to the Problem of Medication Adherence Among Patients with Schizophrenia. Poster session presented at: VA HSR&D National Meeting; 2004 Mar 1; Washington, DC.
  278. Young AS, Mintz J, Cohen AN. Using information systems to improve care for persons with schizophrenia. Psychiatric services (Washington, D.C.). 2004 Mar 1; 55(3):253-255.
  279. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. The Journal of clinical psychiatry. 2004 Feb 1; 65(2):211-6.
  280. Roll JM, Chermack ST, Chudzynski JE. Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: a feasibility study. Psychiatry Research. 2004 Jan 30; 125(1):61-4.
  281. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA : the journal of the American Medical Association. 2003 Nov 26; 290(20):2693-702.
  282. Williams DK, Thrush CR, Armitage TL, Owen RR, Hudson TJ, Thapa PB. The effect of guideline implementation strategies on akathisia outcomes in schizophrenia. Journal of Applied Research. 2003 Oct 30; 3(4):470-482.
  283. Glynn SM. Psychiatric Rehabilitation in Schizophrenia: Advances and Challenges. Clinical Neuroscience Research. 2003 Sep 1; 3:23-33.
  284. Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, Elliott CE, Booth BM. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. American journal of medical quality : the official journal of the American College of Medical Quality. 2003 Jul 1; 18(4):140-6.
  285. Fischer EP, McSweeney J, Pyne JM, Mullings R, Yates T, Naylor AJ. Stakeholder perspectives on sustaining involvement in care for schizophrenia: Autonomy, boredom and decision-making. Paper presented at: International Congress on Schizophrenia Research; 2003 Apr 2; Colorado Springs, CO.
  286. Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophrenia Bulletin. 2003 Apr 1; 29(2):247-56.
  287. Swanson JW, Swartz MS, Hannon MJ, Elbogen EB, Wagner HR, McCauley BJ, Butterfield MI. Psychiatric advance directives: A survey of persons with schizophrenia, family members, and treatments providers. International Journal of Forensic Mental Health. 2003 Mar 1; 2(1):73-86.
  288. Owen RR, Curran GM, Marder SR, Ritchie M. Translating research into practice: Improving medication management for schizophrenia. Paper presented at: VA HSR&D National Meeting; 2003 Feb 14; Washington, DC.
  289. Khanuja K, Austin K, Blow F, Owen R, Valenstein M. Treatment and Outcomes of Patients with Co-morbid Depression and Schizophrenia. Paper presented at: VA HSR&D National Meeting; 2003 Feb 1; Washington, DC.
  290. Owen RR, Cannon D, Thrush CR. Mental Health QUERI Initiative: expert ratings of criteria to assess performance for major depressive disorder and schizophrenia. American journal of medical quality : the official journal of the American College of Medical Quality. 2003 Jan 1; 18(1):15-20.
  291. Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, Alamir S, Buckley P, Bingham CR. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatric services (Washington, D.C.). 2002 Oct 1; 53(10):1319-21.
  292. Barry KL, Blow FC, Dornfeld M, Valenstein M. Aging and schizophrenia: current health services research and recommendations. Journal of geriatric psychiatry and neurology. 2002 Sep 1; 15(3):121-7.
  293. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical care. 2002 Aug 1; 40(8):630-9.
  294. Milner KK, Valenstein M. A comparison of guidelines for the treatment of schizophrenia. Psychiatric services (Washington, D.C.). 2002 Jul 1; 53(7):888-90.
  295. Fischer EP, Shumway M, Owen RR. Priorities of consumers, providers, and family members in the treatment of schizophrenia. Psychiatric services (Washington, D.C.). 2002 Jun 1; 53(6):724-9.
  296. Owen RR, Thrush CR, Hudson TJ, Mallory SR, Fischer EP, Clardy JA, Williams DK. Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia. International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua. 2002 Jun 1; 14(3):199-206.
  297. Sajatovic M, Sultana D, Bingham CR, Buckley P, Donenwirth K. Gender related differences in clinical characteristics and hospital based resource utilization among older adults with schizophrenia. International journal of geriatric psychiatry. 2002 Jun 1; 17(6):542-8.
  298. Young AS, Marder SR. Using collaborative care models to improve the treatment of schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting; 2002 May 21; Philadelphia, PA.
  299. Fischer EP. Family consumer and provider agreement on outcome priorities and service preferences in schizophrenia. Paper presented at: VA MIRECC Annual Retreat; 2002 Apr 24; Jackson, MS.
  300. Hudson TJ. Optimizing medication adherence interventions for schizophrenia. Paper presented at: College of Psychiatric and Neurologic Pharmacists Annual Meeting; 2002 Apr 19; Seattle, WA.
  301. Barry KL, Blow F, Welsh D, Brockmann LM. Gender Differences in the Diagnosis and Treatment of Schizophrenia and Other Serious Mental Illnesses in the VHA: Special Issues for Women Veterans. Paper presented at: VA MIRECC on Women and Schizophrenia Annual Conference; 2002 Apr 15; Washington, DC.
  302. Fischer EP, Shumway M. Agreement on goals, consumer preferences, and involvement in care for schizophrenia. Paper presented at: National Institute of Mental Health Mental Health Services Research Annual Conference; 2002 Apr 2; Washington, DC.
  303. Pyne JM, Sullivan G, Kaplan RM, Williams DK. Sensitivity of generic effectiveness measures to improvement in schizophrenia symptom severity. Paper presented at: VA HSR&D National Meeting; 2002 Feb 14; Washington, DC.
  304. Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughs T, Jeste DV. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. Journal of Clinical Psychopharmacology. 2002 Feb 1; 22(1):11-9.
  305. Russo P, Smith MW. Quality of life in schizophrenia: the relationship between participant self-report and clinical assessment. Paper presented at: AcademyHealth Annual Research Meeting; 2002 Feb 1; Washington, DC.
  306. Russo P, Smith MW, Namjoshi M. Changes in schizophrenia-related total direct medical costs following initiating of olanzapine or resperidone in a privately insured population in the United States. Paper presented at: Collegium Internationale Neuro-Psychopharmacolgicum Annual Congress; 2002 Feb 1; Montréal, Canada.
  307. Russo P, Smith MW, Namjoshi M, Cavazzoni P, Brier A. Changes in antidiabetic medication use following initiation of olanzapine or risperidone among persons with schizophrenia. Paper presented at: American College of Neuropsychopharmacology Annual Meeting; 2002 Feb 1; San Juan, Puerto Rico.
  308. Valenstein M, Copeland L, Blow F, McCarthy DM, Zeber J, Gillon L. Pharmacy Data Identifies Poorly Adherent Patients with Schizophrenia at Increased Risk for Admission. Paper presented at: VA HSR&D National Meeting; 2002 Feb 1; Washington, DC.
  309. Cradock J, Young AS, Sullivan G. The accuracy of medical record documentation in schizophrenia. The journal of behavioral health services & research. 2001 Nov 1; 28(4):456-65.
  310. Pyne JM, Sullivan G, Kaplan RM, Williams DK. Comparing the sensitivity of generic effectiveness measures to symptom improvement in person with schizophrenia. Paper presented at: Society for Medical Decision Making Annual Meeting; 2001 Oct 31; San Diego, CA.
  311. Fischer EP, Shumway M. Do stakeholders agree on priorities in treatment for schizophrenia? Extent of agreement within individual consumer-provider-family sets. Paper presented at: International Congress on Schizophrenia Research; 2001 Sep 25; Whistler, Canada.
  312. Hudson TJ. Schizophrenia. In: Ginsburg DB, editor. PharmPrep 1st Edition: Case-Based Board Review. Bethesda, MD: American Society of Health-system Pharmacists; 2001. 280-285 p.
  313. Cradock JA, Young AS, Sullivan G. The accuracy of medical record documentation in schizophrenia. Paper presented at: Western Psychological Association Annual Convention; 2001 Jul 1; Maui, HI.
  314. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. The Journal of clinical psychiatry. 2001 Jul 1; 62(7):545-51.
  315. Cradock JA, Young AS, Sullivan G. The accuracy of medication treatment for schizophrenia. Paper presented at: AcademyHealth Annual Research Meeting; 2001 Jun 11; Atlanta, GA.
  316. Pyne JM, Sullivan G, Williams DK. Quality-adjusted life year measurement in persons with schizophrenia. Paper presented at: American Psychological Association Annual Convention; 2001 May 14; New Orleans, LA.
  317. Young AS, Sullivan G. The quality of medication treatment for schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting; 2001 May 8; New Orleans, LA.
  318. Owen RR. Closing the efficacy/effectiveness gap in psychopharmacology: Strategies for implementing schizophrenia guidelines. Paper presented at: American Psychiatric Association Annual Meeting; 2001 May 1; New Orleans, LA.
  319. Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV. Social skills performance assessment among older patients with schizophrenia. Schizophrenia Research. 2001 Mar 30; 48(2-3):351-60.
  320. Pyne JM, Bean D, Sullivan G. Characteristics of patients with schizophrenia who do not believe they are mentally ill. The Journal of nervous and mental disease. 2001 Mar 1; 189(3):146-53.
  321. Fischer EP, Shumway M. Stakeholder preferences in schizophrenia: Agreement within consumer-provider-family sets. Paper presented at: VA HSR&D National Meeting; 2001 Feb 19; Washington, DC.
  322. Pyne JM, Sullivan G, Kaplan RM, Williams DK. Comparison of generic effectiveness measures in veterans with schizophrenia. Paper presented at: VA HSR&D National Meeting; 2001 Feb 19; Washington, DC.
  323. Valenstein M, Blow FC, Copeland L, McCarthy J, Gillon L, Zeber J, Bingham CR. Adherence with antipsychotics among patients with Schizophrenia. Paper presented at: VA HSR&D National Meeting; 2001 Feb 1; Washington, DC.
  324. Owen RR, Thrush CR, Kirchner JE, Fischer EP, Booth BM. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua. 2000 Dec 1; 12(6):475-82.
  325. Fischer EP. Schizophrenia outcome priorities and treatment preferences: Agreement among stakeholders. Paper presented at: Association for Health Services Research Annual Meeting; 2000 Jun 15; Los Angeles, CA.
  326. Roberts JS, Blow FC, Copeland LA, Barry KL, Van Stone W. Age-group differences in treatment outcomes for male veterans with severe schizophrenia: a three-year longitudinal study. Journal of geriatric psychiatry and neurology. 2000 Jun 1; 13(2):78-86.
  327. Hamner MB, Frueh BC, Ulmer HG, Huber MG, Twomey TJ, Tyson C, Arana GW. Psychotic features in chronic posttraumatic stress disorder and schizophrenia: comparative severity. The Journal of nervous and mental disease. 2000 Apr 1; 188(4):217-21.
  328. Fischer EP, Owen RR. Quality of public sector care for schizophrenia in Arkansas. Mental health services research. 1999 Dec 1; 1(4):213-21.
  329. Manning WG, Liu CF, Stoner TJ, Gray DZ, Lurie N, Popkin M, Christianson JB. Outcomes for Medicaid beneficiaries with schizophrenia under a prepaid mental health carve-out. The journal of behavioral health services & research. 1999 Nov 1; 26(4):442-50.
  330. Hudson TJ, Owen RR, Mason BL, Lancaster AE. Use of computerized data to assess adherence to schizophrenia practice guidelines. Presented at: VA HSR&D National Meeting; 1999 Sep 15; Washington, DC.
  331. Pyne JM. WHO Disablement Assessment Schedule: An application in schizophrenia. Paper presented at: American Psychiatric Association Annual Workshop; 1999 Aug 15; Washington, DC.
  332. Hudson TJ, Owen RR, Lancaster AE, Mason L. The feasibility of using automated data to assess guideline-concordant care for schizophrenia. Journal of medical systems. 1999 Aug 1; 23(4):299-307.
  333. Kales HC, Dequardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1999 Apr 1; 23(3):547-56.
  334. Mares A, McGuire J. Recidivism among Veterans with Schizophrenia Living in Board and Care: An Outcome Evaluation of the Community Residential Care Program. Paper presented at: VA HSR&D National Meeting; 1999 Feb 24; Washington, DC.
  335. Kirchner JE, Owen RR, Nordquist C, Fischer EP. Diagnosis and management of substance use disorders among inpatients with schizophrenia. Psychiatric services (Washington, D.C.). 1998 Jan 1; 49(1):82-5.

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.